Generative AI showed promise in drug discovery — but scaling AI from isolated models to real-world scientific workflows remains a major challenge.
In this webinar, Dr. Samuel Genheden, Director of AstraZeneca’s Deep Chemistry team, will discuss the evolution from early generative AI approaches to sophisticated multi-agent scientific workflows supporting drug discovery.
The session will explore how autonomous AI agents can assist molecular design, reaction planning, and scientific decision-making, along with the practical challenges of deploying these systems at scale.
Elsevier will also discuss how it is making agentic AI practical for drug R&D through modular, purpose-built agents and smart connectors delivered via MCP and API interfaces to support drug discovery workflows — powered by trusted life sciences data from scientific literature, patents, and regulatory documents.
Agenda
From generative AI to multi-agent scientific workflows
AI agents for molecular design and reaction planning
Samuel Genheden leads the Deep Chemistry team in Discovery Sciences, AstraZeneca R&D. He received his PhD in theoretical chemistry from Lund University in 2012, having studied computational methods to estimate ligand-binding affinities. He...
Ivan Krstic, PhD, is a senior product leader with over a decade of experience in life sciences information solutions. As Senior Director of Product Marketing at Elsevier, he oversees a diverse portfolio of digital solutions and data products,...